Latest BAKER BROS. ADVISORS LP Stock Portfolio

BAKER BROS. ADVISORS LP Performance:

2024 Q4: -2.73%YTD: 1.57%2023: -0.24%

Performance for 2024 Q4 is -2.73%, and YTD is 1.57%, and 2023 is -0.24%.

About BAKER BROS. ADVISORS LP and 13F Hedge Fund Stock Holdings

BAKER BROS. ADVISORS LP is a hedge fund based in NEW YORK, NY. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $23.2 Billions. In it's latest 13F Holdings report, BAKER BROS. ADVISORS LP reported an equity portfolio of $9.4 Billions as of 31 Dec, 2024.

The top stock holdings of BAKER BROS. ADVISORS LP are INCY, BGNE, ACAD. The fund has invested 22.7% of it's portfolio in INCYTE CORPORATION and 18.8% of portfolio in BEIGENE, LTD.

The fund managers got completely rid off TANGO THERAPEUTICS, INC. (TNGX), CRINETICS PHARMACEUTICALS, INC. (CRNX) and DBV TECHNOLOGIES S.A. (DBVT) stocks. They significantly reduced their stock positions in BIOMEA FUSION, INC. (BMEA), SAGIMET BIOSCIENCES INC. and BEIGENE, LTD. (BGNE). BAKER BROS. ADVISORS LP opened new stock positions in GRAIL, INC., CANDEL THERAPEUTICS, INC. (CADL) and VIR BIOTECHNOLOGY, INC. (VIR). The fund showed a lot of confidence in some stocks as they added substantially to STRUCTURE THERAPEUTICS INC., IONIS PHARMACEUTICALS, INC. (IONS) and CRISPR THERAPEUTICS AG (CRSP).

BAKER BROS. ADVISORS LP Annual Return Estimates Vs S&P 500

Our best estimate is that BAKER BROS. ADVISORS LP made a return of -2.73% in the last quarter. In trailing 12 months, it's portfolio return was 1.57%.

New Buys

Ticker	$ Bought
ionis pharmaceuticals, inc.	29,543,600
grail, inc.	29,097,700
candel therapeutics, inc.	25,883,600
vir biotechnology, inc.	7,960,520
intellia therapeutics, inc.	7,510,390
biontech se	5,131,280
disc medicine, inc.	4,884,970
dbv technologies s.a.	4,515,800

New stocks bought by BAKER BROS. ADVISORS LP

Additions

Ticker	% Inc.
structure therapeutics inc.	322
ionis pharmaceuticals, inc.	60.16
crispr therapeutics ag	55.15
merus n.v.	50.00
neurogene inc.	47.9
celcuity inc.	42.86
immunovant, inc.	39.37
kala bio, inc.	34.84

Additions to existing portfolio by BAKER BROS. ADVISORS LP

Reductions

Ticker	% Reduced
biomea fusion, inc.	-31.15
sagimet biosciences inc.	-31.04
beigene, ltd.	-9.81
rhythm pharmaceuticals, inc.	-4.91

BAKER BROS. ADVISORS LP reduced stake in above stock

Sold off

Ticker	$ Sold
dbv technologies s.a.	-5,114,990
alector, inc.	-4,321,050
tango therapeutics, inc.	-5,775,000
aerovate therapeutics, inc.	-1,314,480
crinetics pharmaceuticals, inc.	-5,310,670
newamsterdam pharma company n.v.	-1,605,400
biocryst pharmaceuticals, inc.	-575,913
pfizer inc.	-1,012,900

BAKER BROS. ADVISORS LP got rid off the above stocks

Sector Distribution

BAKER BROS. ADVISORS LP has about 96.7% of it's holdings in Healthcare sector.

Sector	%
Healthcare	96.7
Others	3.3

Market Cap. Distribution

BAKER BROS. ADVISORS LP has about 45.8% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	31.2
LARGE-CAP	26.7
MEGA-CAP	19.1
SMALL-CAP	15.6
UNALLOCATED	3.8
MICRO-CAP	3.4

Stocks belong to which Index?

About 70.4% of the stocks held by BAKER BROS. ADVISORS LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	47.4
Others	29.6
S&P 500	23

Top 5 Winners (%)		%
ALGS	aligos therapeutics, inc.	360.1 %
DBVT	dbv technologies s.a.	296.1 %
KOD	kodiak sciences inc.	281.2 %
TARA	protara therapeutics, inc.	188.5 %
SRZN	surrozen, inc.	107.8 %

Top 5 Winners ($)		$
MDGL	madrigal pharmaceuticals, inc.	190.3 M
ACAD	acadia pharmaceuticals inc.	127.3 M
KOD	kodiak sciences inc.	127.1 M
INCY	incyte corporation	91.3 M
RYTM	rhythm pharmaceuticals, inc.	22.8 M

Top 5 Losers (%)		%
IGMS	igm biosciences, inc.	-63.0 %
SANA	sana biotechnology, inc.	-60.8 %
GBIO	generation bio co.	-57.1 %
HOOK	hookipa pharma inc.	-53.3 %
FATE	fate therapeutics, inc.	-51.7 %

Top 5 Losers ($)		$
BGNE	beigene, ltd.	-400.5 M
SMMT	summit therapeutics inc.	-99.0 M
BCYC	bicycle therapeutics plc	-92.6 M
IGMS	igm biosciences, inc.	-42.7 M
KYMR	kymera therapeutics, inc.	-42.6 M

BAKER BROS. ADVISORS LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS LP has 93 stocks in it's portfolio. About 76.5% of the portfolio is in top 10 stocks. BGNE proved to be the most loss making stock for the portfolio. MDGL was the most profitable stock for BAKER BROS. ADVISORS LP last quarter.

Last Reported on: 14 Feb, 2025

	Ticker	Namesorted descending	% Portfolio	Shares Held	$ Value	Type	% Change
	INCY	incyte corporation	22.68	30,739,500	2,123,170,000	added	0.00
Historical Trend of INCYTE CORPORATION Position Held By BAKER BROS. ADVISORS LP What % of Portfolio is INCY?: Number of INCY shares held: Change in No. of Shares Held:
	BGNE	beigene, ltd.	18.81	9,531,880	1,760,630,000	reduced	-9.81

	ACAD	acadia pharmaceuticals inc.	8.40	42,877,900	786,810,000	unchanged	0.00

	MDGL	madrigal pharmaceuticals, inc.	6.51	1,974,590	609,299,000	unchanged	0.00

	SMMT	summit therapeutics inc.	4.66	24,424,900	435,862,000	unchanged	0.00

	RVMD	revolution medicines, inc.	3.71	7,936,970	347,163,000	added	4.86

	INSM	insmed incorporated	3.69	5,006,860	345,674,000	added	13.38

	RYTM	rhythm pharmaceuticals, inc.	3.64	6,084,250	340,596,000	reduced	-4.91

	KYMR	kymera therapeutics, inc.	2.58	5,995,930	241,216,000	unchanged	0.00

	KOD	kodiak sciences inc.	1.84	17,310,500	172,239,000	unchanged	0.00

	EWTX	edgewise therapeutics, inc.	1.76	6,155,940	164,364,000	added	5.41

	BCYC	bicycle therapeutics plc	1.63	10,885,400	152,395,000	added	15.8

	REPL	replimune group, inc.	1.43	11,045,300	133,759,000	unchanged	0.00

	ALKS	alkermes plc	1.28	4,181,750	120,267,000	unchanged	0.00

	INSM	insmed incorporated	0.99	42,850,000	92,928,700	unchanged	0.00

	TRDA	entrada therapeutics, inc.	0.90	4,865,820	84,130,000	unchanged	0.00

	ABCL	abcellera biologics inc.	0.86	27,525,600	80,650,100	unchanged	0.00

	DNLI	denali therapeutics inc.	0.81	3,731,700	76,051,900	unchanged	0.00

	NRIX	nurix therapeutics, inc.	0.78	3,882,120	73,139,200	unchanged	0.00

		argenx se	0.74	111,904	68,821,000	unchanged	0.00